Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Peptidyl arginine deiminase type 3 (PADI3) is a calcium-dependent enzyme. It catalyzes the post-translational modification of proteins by converting arginine residues to citrulline, a process known as deimination or citrullination. PADI3 is most highly expressed in differentiating keratinocytes in the epidermis and in hair follicles, where it modifies structural proteins (such as trichohyalin, filaggrin, and selected keratins) crucial for hair shaft formation and epidermal barrier function. The enzyme’s activity modulates protein-protein interactions and protein structure, impacting hair morphology and skin barrier integrity. Mutations in PADI3 leading to loss of function are a principal cause of uncombable hair syndrome, a rare disorder of hair shaft shape and integrity. PADI3 is a member of the peptidyl arginine deiminase family, distinguished by its substrate specificity and tissue expression pattern.
PAD inhibitors (experimental, not approved): Irreversible or reversible inhibition of the catalytic active site preventing conversion of protein-bound arginine to citrulline, thereby inhibiting downstream protein modification and function
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Peptidyl arginine deiminase type 3 (PADI3).